TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
LFCR

Lifecore Biomedical Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

4.50$ +0.0% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios LFCR
Line item 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Valuation
28.9 36.6 15.9 133.5 17.7
0.7 0.6 0.7 0.8 0.5 1.9 3.5 1.5 2.2 1.7 1.8 1.4
1.8 1.5 1.7 1.6 1.0 1.4 1.7 2.6 2.8 18.8 177.2
0.7 0.6 0.7 0.8 0.8 3.2 5.4 2.3 4.4 2.6 2.8 2.4
12.7 14.6 16.9 18.4 37.7 9.3 37.2
45.2 57.5 30.0
2.2% -6.1% 1.7% -3.5% -10.1% -14.0% -2.5% -18.7% -21.7% -8.5% -5.8% 3.3%
Margins
12.1% 13.1% 15.6% 14.9% 14.5% 24.6% 38.6% 27.1% 35.1% 32.6% 31.3% 31.4%
3.4% -3.7% 2.9% 2.3% -1.4% -16.2% -8.7% -1.9% -10.6% -6.9% -13.4% -1.0%
2.5% -2.2% 2.0% 4.7% 0.4% -23.9% -32.0% -52.4% -104.9% 9.4% -30.0% -23.8%
1.6% -3.5% 1.3% -2.6% -5.1% -27.3% -8.7% -28.3% -47.2% -14.1% -10.6% 4.8%
Returns
6.2% -5.5% 4.7% 9.8% 0.8% -16.5% -15.9% -90.3% -132.9% 106.2% -2,898.0%
3.9% -3.4% 3.0% 6.1% 0.4% -7.1% -6.4% -33.0% -42.5% 4.7% -16.2% -13.3%
Balance Sheet & Debt
-5.8 1.5 2.5 29 148 194 194 142 243 117 123 119
-0.2 0.1 1.2 6.3 18.9 3.3 14.5
63.0% 61.4% 63.3% 62.4% 52.0% 42.7% 40.3% 36.6% 32.0% 4.5% 0.6% -6.1%
0.0 0.1 0.0 0.1 0.6 0.8 1.0 1.3 2.8 11.1 97.9
Per Share
0.50 -0.43 0.38 0.89 0.07 -1.31 -1.10 -3.30 -3.96 0.33 -1.11 -0.82
19.73 19.93 19.25 18.78 19.49 5.49 3.44 6.30 3.78 3.50 3.70 3.46
7.99 7.76 8.20 9.05 9.44 7.92 6.92 3.66 2.98 0.31 0.04 -0.38
0.32 -0.70 0.24 -0.49 -1.00 -1.50 -0.30 -1.78 -1.78 -0.49 -0.39 0.17

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?